haloperidol has been researched along with Sensation Disorders in 1 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Sensation Disorders: Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Romero, E | 1 |
Ali, C | 1 |
Molina-Holgado, E | 1 |
Castellano, B | 1 |
Guaza, C | 1 |
Borrell, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
Intervention | Change in BACS Composite Score (Mean) |
---|---|
Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
Intervention | Change in PANSS Total Score (Mean) |
---|---|
Tocilizumab | -2.6 |
1 other study available for haloperidol and Sensation Disorders
Article | Year |
---|---|
Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Brain Chemistry; Cytok | 2007 |
Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Brain Chemistry; Cytok | 2007 |
Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Brain Chemistry; Cytok | 2007 |
Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Brain Chemistry; Cytok | 2007 |